Benzinga | Nov 13, 2020 06:50AM EST

Aerie Pharma Reports Received Positive CHMP Opinion For Roclanda In EU

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda(r) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.

The CHMP positive opinion is a scientific recommendation for marketing authorisation, which is referred to the European Commission for a final decision on the Company's MAA. The final decision is expected in approximately two months and will be applicable to all European Union member states plus Iceland, Norway and Liechtenstein.

"We are delighted that the CHMP has adopted a positive opinion for Roclanda(r)," said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. "We look forward to the European Commission's final decision on the MAA for Roclanda(r), which is expected by early next year."

Roclanda(r) is currently marketed as Rocklatan(r) in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension.